ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

ACC 2020 An antibody against angiopoietin-like protein 3 (ANGPTL3) resulted in lowering of LDL-c in homozygous FH patients, independent of LDL receptor function.

ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.

ACC 2020 This study showed that the angiopoietin-like protein 3 inhibitor evinacumab substantially reduces LDL-c in patients with homozygous Familial Hypercholesterolemia (HoFH), regardless of LDL receptor function.

Among individuals with comparable levels of LDL-c, individuals with monogenic FH had the highest risk for composite CVD events followed by individuals with polygenic hypercholesterolemia compared to those with nongenetic hypercholesterolemia.

The open-label TAUSSIG study evaluated treatment with evolocumab during a median follow-up of 4.1 years and found a similar safety profile and good LDL-c lowering in HoFH and HeFH patients

The FIND FH is a machine learning model that identified a large number of individuals with probable FH who had not previously been diagnosed in two distinct types of large medical databases.

AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

Final results from the open-label OSLER-1 study on evolocumab show long-term reduction in LDL-C levels without attenuation of the LDL-lowering effect and consistent safety and tolerability profiles during 5-years.

CSI Paris Cilie van 't Klooster asks prof. Mach to summarize the most important changes in the 2019 ESC/EAS dyslipidemia guidelines.

Long-term follow-up of persons with FH who started statin therapy in childhood shows that progression of cIMT was slowed to the rate seen in unaffected siblings, and CV event risk was reduced.

The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.